Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-11-08, Stock:PFE, The news for the past five days is as follows:
2018-11-01: NEWS1: Pfizer and Coca-Cola Earnings Help Safer Income Stocks Shine.NEWS2: Pfizer cut to market perform at BMO.NEWS3: BMO: ‘Significant Headwinds’ Will Cap Pfizer Upside.NEWS4: White House wants to crack down on drug companies before the midterm elections.NEWS5: BMO Downgrades Pfizer After Q3 Print, Says Risk-Reward 'Fairly Balanced'.NEWS6: Edited Transcript of PFE earnings conference call or presentation 30-Oct-18 2:00pm GMT.NEWS7: Has Pfizer (PFE) Outpaced Other Medical Stocks This Year?.NEWS8: Here's What Exact Sciences Just Said About Its Future.NEWS9: Here's What Exact Sciences Just Said About Its Future.NEWS10: Zoetis Inc Earnings, Revenue beat in Q3.NEWS11: 3 Pharma Stocks to Make a Portfolio Feel Better.NEWS12: Pfizer weighing sale of women's health portfolio - Bloomberg.NEWS13: Health Care Sector Update for 11/01/2018: TEVA, NVO, SNN, JNJ, PFE, ABT, MRK, AMGN.NEWS14: Health Care Sector Update for 11/01/2018: TEVA, NVO, SNN, JNJ, PFE, ABT, MRK, AMGN.NEWS15: Here&apos;s What Exact Sciences Just Said About Its Future.NEWS16: Pfizer downgraded by BMO: &apos;Significant headwinds&apos; will cap the drugmaker&apos;s stock run.NEWS17: Stocks making the biggest move premarket: DWDP, NFX, ECA, AAPL, CI & more.NEWS18: Pfizer will go back to price hikes ‘as normal’ come January, CEO suggests.
2018-11-02: NEWS1: FDA approves Pfizer's treatment for certain lung cancer patients.NEWS2: Exelixis (EXEL) Q3 Earnings, Revenues Beat on Cabometyx Sales.NEWS3: Exelixis (EXEL) Q3 Earnings, Revenues Beat on Cabometyx Sales.NEWS4: Stocks finish lower after a volatile trading session.NEWS5: U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC.NEWS6: Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO.NEWS7: Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO.NEWS8: Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates.NEWS9: Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates.NEWS10: Here's Why Exelixis Inc. Stock Is Surging Today.NEWS11: Here's Why Exelixis Inc. Stock Is Surging Today.NEWS12: Pfizer’s Earnings Projections for 2018.NEWS13: SQQQ, FTXH: Big ETF Inflows.NEWS14: SQQQ, FTXH: Big ETF Inflows.NEWS15: Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO.NEWS16: Revenue Projections for Pfizer in 2018.NEWS17: What Does Gilead Sciences’ Bottom-Line Trend Indicate?.NEWS18: Gilead Sciences’ Operational Performance.NEWS19: Gilead Sciences: An Update for Investors.NEWS20: AbbVie Earnings, Revenue beat in Q3.NEWS21: Here’s How Pfizer Stock Moved in October.NEWS22: Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus.NEWS23: Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus.NEWS24: Dow 30 Stock Roundup: Apple, Coca-Cola, DowDuPont Earnings Impress.NEWS25: Dow 30 Stock Roundup: Apple, Coca-Cola, DowDuPont Earnings Impress.NEWS26: Report: Exploring Fundamental Drivers Behind Pfizer, eBay, ABM Industries, Quad Graphics, FireEye, and BJ's Restaurants — New Horizons, Emerging Trends, and Upcoming Developments.NEWS27: Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus.NEWS28: Dow 30 Stock Roundup: Apple, Coca-Cola, DowDuPont Earnings Impress.NEWS29: Pfizer and Coca-Cola Earnings Help Safer Income Stocks Shine.NEWS30: Pfizer and Coca-Cola Earnings Help Safer Income Stocks Shine.
2018-11-05: NEWS1: Biogen Stock Rebounds After Impressive Q3 Earnings.NEWS2: Biogen Stock Rebounds After Impressive Q3 Earnings.NEWS3: Corcept (CORT) Q3 Earnings In Line, Revenues Miss Estimates.NEWS4: Corcept (CORT) Q3 Earnings In Line, Revenues Miss Estimates.NEWS5: A Look at Teva Pharmaceutical’s Third-Quarter Earnings.NEWS6: Bulls & Bears Of The Week: Amazon, Apple, Ford, GE And More.NEWS7: Teva Pharmaceutical’s Performance in the Third Quarter.NEWS8: Biogen Stock Rebounds After Impressive Q3 Earnings.NEWS9: Xtandi’s Label Expansion Drives Future Growth.NEWS10: Hedge Funds Are Piling Into This Stock.NEWS11: Health Care Sector Update for 11/05/2018: BTAI, FOLD, TFX, PFE, JNJ, ABT, MRK, AMGN.NEWS12: Health Care Sector Update for 11/05/2018: BTAI, FOLD, TFX, PFE, JNJ, ABT, MRK, AMGN.NEWS13: Ibrance: A Key Growth Driver for Pfizer.NEWS14: Gilead Sciences: Analysts’ Recommendations.NEWS15: Analyzing Pfizer’s Expense Projections for 2018.NEWS16: Analyzing Gilead Sciences’ HIV Portfolio.
2018-11-06: NEWS1: Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know.NEWS2: MARKETS:  Pharma stocks making moves ahead of midterms.NEWS3: Eli Lilly's Conservative Pricing Offers Protection From Political Pressure.NEWS4: Beaten-Down Pharma ETFs to Buy Post Q3 Results.NEWS5: Beaten-Down Pharma ETFs to Buy Post Q3 Results.NEWS6: Can Low Volatility ETFs Protect Your Portfolio?.NEWS7: Can Low Volatility ETFs Protect Your Portfolio?.NEWS8: Notable ETF Inflow Detected - DGRO, PFE, ABBV, CMCSA.NEWS9: Notable ETF Inflow Detected - DGRO, PFE, ABBV, CMCSA.NEWS10: Ex-Dividend Reminder: AmeriGas Partners, Bio-Techne and Pfizer.NEWS11: Ex-Dividend Reminder: AmeriGas Partners, Bio-Techne and Pfizer.NEWS12: Vaccines Are an Important Growth Driver for Pfizer.NEWS13: Xeljanz: PFE’s Immunology and Inflammation Growth Driver.NEWS14: New Clinical Oncology Collaboration Between Nektar and Pfizer to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers.NEWS15: See what the IHS Markit Score report has to say about Pfizer Inc..NEWS16: Pfizer’s Eliquis Sees Double-Digit Revenue Growth Year-to-Date.NEWS17: Nektar Therapeutics And Pfizer Enter Into New Clinical Oncology Collaboration.NEWS18: Nektar Therapeutics And Pfizer Enter Into New Clinical Oncology Collaboration.
2018-11-07: NEWS1: After Hours Most Active for Nov 7, 2018 :  V, LIN, S, USX, CTL, PFE.NEWS2: After Hours Most Active for Nov 7, 2018 :  V, LIN, S, USX, CTL, PFE.NEWS3: These 5 Dow Jones Stocks Just Made This Bullish Move.NEWS4: What AbbVie’s Bottom Line Trend Indicates.NEWS5: A Look at AbbVie’s Operational Performance.NEWS6: How AbbVie Is Positioned in November.NEWS7: MARKETS:  Oil heading into bear market territory.NEWS8: Pfizer Rises 3%.NEWS9: 'We have a lot of things in common' — Trump wants to work with Democrats on infrastructure, drugs.NEWS10: Trump says he hopes to work with Democrats on infrastructure, drug pricing.NEWS11: Tariffs, Drug Prices, Legislative Gridlock: What Economists Are Watching Following The Midterm Election.NEWS12: NMC Healthcare Sukuk Limited -- Moody's assigns Ba1 rating to NMC's trust certificates.NEWS13: Why Nektar Therapeutics Fell 36.5% in October.NEWS14: Why Nektar Therapeutics Fell 36.5% in October.NEWS15: Sanofi Eczema Drug Dupixent's sBLA Gets Priority Review.NEWS16: Sanofi Eczema Drug Dupixent's sBLA Gets Priority Review.NEWS17: Health Care Sector Update for 11/07/2018: INGN, AXDX, FOMX, JNJ, PFE, ABT, MRK, AMGN.NEWS18: Health Care Sector Update for 11/07/2018: INGN, AXDX, FOMX, JNJ, PFE, ABT, MRK, AMGN.NEWS19: Pfizer, Inc. (PFE) Ex-Dividend Date Scheduled for November 08, 2018.NEWS20: Pfizer, Inc. (PFE) Ex-Dividend Date Scheduled for November 08, 2018.NEWS21: Why Pfizer’s Rare Disease Portfolio Offers a Unique Opportunity.NEWS22: Validea James P. O'Shaughnessy Strategy Daily Upgrade Report - 11/7/2018.NEWS23: Validea James P. O'Shaughnessy Strategy Daily Upgrade Report - 11/7/2018.

Answer: Decrease